Data from a phase II trial examining the safety and efficacy of nivolumab, an antibody against the programmed cell death-1 (PD-1) immune checkpoint, in 20 patients with platinum-resistant ovarian cancer were recently published [137]. This evidence concerns the gene PDCD1 and ovarian carcinoma.